Betsy Morrow
National Institutes of Health · 48 works · 1,150 citations · h-index 14
Top works
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- Mutations of epigenetic regulatory genes are common in thymic carcinomas
- Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
- A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN
- Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression
- Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma
- A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors
- Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma
- Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
- Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models
- Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
- Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.
- Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.
- Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma
- A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN.
- Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells
- Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer
- Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.
- Transcriptomics based prediction of survival and response to therapy in malignant mesothelioma